Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide Sildenafil therapy for subjects who completed
A1481156 study and are judged by the investigator to derive clinical benefit from continued
treatment with Sildenafil, prior to reimbursement and availability for subjects in the
Russian Federation.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.